Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk A/S’ NVO Awiqli (insulin icodec-abae), marking ...

Novo Nordisk announced today that it received FDA approval for Awiqli, the first and only once-weekly, long-acting basal ...

Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. Click here to read an ...

The global insulin delivery devices market is experiencing strong expansion as the prevalence of diabetes continues to rise worldwide. Insulin delivery devices play a crucial role in managing blood ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

But without insulin the sugar can’t be used, so the starvation response continues, and the body resorts to burning fatty ...

The Bengaluru-based drugmaker has approvals for biosimilar versions of Insulin Glargine, Insulin Aspart and Human Insulin.

The Smart Insulin Pens Market is rapidly gaining momentum as healthcare systems worldwide shift toward more advanced, patient ...

Crystal Leisure Centre in Stourbridge have apologised for the family's experience at the centre and 'the unnecessary distress ...

Diabetes hardware company embecta aims to look beyond insulin and reshape itself into a more varied drug delivery provider—and it’s kick-starting that effort with the acquisition of a glo | Embecta ...